longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Weekly Recap | Strive +19.32%, most brokers rate it buy

Weekly Review
Aug 29, 2026 at 05:15 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Strive rallied 19.32% this week to close at $21.74, against a 0.49% rise in the S&P 500, outperforming the benchmark by 18.83 percentage points. The move was a spike-and-fade: the stock opened at $18.76 on Monday, climbed into Thursday when it touched a weekly high of $24.38, then pulled back on Friday to close at $21.74. Weekly amplitude reached 31.08%, with daily turnover averaging 12.51m shares, well above the prior median.

The Week

Strive rallied 19.32% this week to close at $21.74, against a 0.49% rise in the S&P 500, outperforming the benchmark by 18.83 percentage points. The move was a spike-and-fade: the stock opened at $18.76 on Monday, climbed into Thursday when it touched a weekly high of $24.38, then pulled back on Friday to close at $21.74. Weekly amplitude reached 31.08%, with daily turnover averaging 12.51m shares, well above the prior median.\n\n## Key Events\n\nBitcoin accumulation dominated the story. On Tuesday the company disclosed an $81.5m purchase of 1,110 Bitcoin, taking its total holdings to 21,000 BTC; shares rose roughly 11% that day. Over the following sessions, options desk coverage flagged sharp gains in call contracts, up 223%, 134% and 162% from Monday to Thursday. By Saturday, reports noted Strive added 2,680 Bitcoin in five days, marking what the news called its best week ever.\n\n## Analyst Ratings\n\nFive brokers cover the stock, with four issuing buy ratings and one at overweight; none rate it hold, underweight or sell. Consensus is strong buy, with a target of $26.6, about 22.36% above the latest close of $21.74. The target range runs from $16 to $36, indicating wide dispersion. Among 141 medical device names, Strive’s rating rank sits 56th.\n\n## The Week Ahead\n\nSeveral US macro releases follow next week: Dallas Fed manufacturing activity on Monday, S&P Global and ISM manufacturing PMIs plus JOLTS job openings on Tuesday, and ADP private payrolls, factory orders and EIA crude stockpiles on Wednesday. For a high-volatility name like Strive, shifts in macro liquidity expectations can weigh on risk appetite, so the post-data market tone will matter.\n\n## In Short\n\nStrive’s rally coincided with large Bitcoin purchases and a stretch of surging call options, signalling elevated trading heat. Yet the company posts negative earnings and a PB near 2.33, with no margin of safety on valuation. The latest session showed large-lot money turning net seller while small-lot orders were net buyers, a split in direction. Brokers remain consistently buy-rated and their consensus target sits more than 20% above spot. The question now is whether accumulation continues and whether that institutional optimism holds up in a choppy tape.\n\nThis article is generated by LongbridgeAI from market data, for information only and not investment advice.

Login to unlock1,893characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Strive

Strive

ASST.US

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI